.png?width=200&height=50&name=Hemostemix%20Logos%20(400%20x%20100%20px).png "Hemostemix Logos (400 x 100 px)")
LIVE WEBINAR — MAY 5, 2026
When Standard Heart Treatment Isn't Enough
Prof. Dr. Ernst von Schwarz and Dr. York N. Hsiang on investigational cell therapy for angina, heart failure, and ischemic cardiomyopathy
Date
Tuesday, May 5
Time
12:00 PM EST
Format
Live on Zoom
Duration
60 Minutes
Date
Tuesday, May 5
Time
12:00 PM EST
Format
Live on Zoom
Duration
60 Minutes
This session
A conversation that most physicians never have in public.
Prof. Dr. von Schwarz has spent 30 years studying what the body can do when given the right biological tools. Dr. Hsiang led the Phase II trial. On May 5 they talk together, live, for the first time.
After you register
Here is what happens next.
You will receive a confirmation email immediately with your Zoom link. We will send you a reminder 48 hours before and again the morning of May 5. If you cannot attend live, register anyway and we will send you the full replay.
ACP-01 is an investigational therapy. This webinar is for informational purposes only and does not constitute medical advice. By submitting this form you consent to receive emails, SMS text messages, and phone calls (including by autodialer) from Hemostemix Inc. Message and data rates may apply. Opt out anytime. Consent is not required as a condition of purchase. | THIS NOTICE MUST BE PROVIDED TO YOU UNDER FLORIDA LAW. This physician performs one or more stem cell therapies that have not yet been approved by the United States Food and Drug Administration. You are encouraged to consult with your primary care provider before undergoing any stem cell therapy.
Prof. Dr. Ernst von Schwarz
MD, PhD, FESC, FACC, FSCAI
Cedars Sinai · UCLA
Dr. York N. Hsiang
MB ChB, MHSc, FRCSC
Phase II PI · UBC
What you will hear in 60 minutes
-
Why stem cell therapy is being studied for patients whose hearts have stopped responding to conventional treatment
-
What the investigational data shows and what Prof. Dr. von Schwarz has observed in cardiac practice over 30 years
-
How patients in Florida are currently accessing ACP-01 through a physician-supervised pathway
⚖️ Florida SB 1768 — Mandatory Statutory Notice (Required in all advertisements)
THIS NOTICE MUST BE PROVIDED TO YOU UNDER FLORIDA LAW. This physician performs one or more stem cell therapies that have not yet been approved by the United States Food and Drug Administration. You are encouraged to consult with your primary care provider before undergoing any stem cell therapy.
ACP-01 is an investigational autologous angiogenic cell therapy. It is not approved by the FDA or any other regulatory authority. This webinar is for informational purposes only and does not constitute medical advice, a treatment recommendation, or a clinical consultation. Individual patient outcomes may vary. Speak with your physician about your specific medical situation.
Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF | FSE: 2VF0)